Table 1.

Randomized controlled trials examining the effects of depression treatment on disease outcomes

Disease	Authors	# Subjects	Time	Treatment	Control Condition	Outcome Measure for Depression	Outcome Measure for Disease
Coronary Heart Disease	Berkman et al. (2003)	1332	24 weeks 2 year follow-up	CBT	Usual Care	+ BDI + HRSD	= Mortality
	Glassman et al., (2003)/ Serebruary et al., (2003)	369	24 weeks	Sertraline	Placebo	=HRSD	= Mortality + platelet activation
	Strik et al., (2000)	54	9 weeks	Fluoxetine	Placebo	= HRSD	= Cardiac Events
	van Melle et al., (2007)	331	18 months	Mirtazapine or Citalopram or psychotherapy	Usual Care	= BDI = ICD-10	= Cardiac Events
Diabetes	Katon et al., (2004)	329	12 months	Antidepressant or psychotherapy	Usual Care	+ SCL-90	= Glycemin control
	Lustman et al., (2000)	60	8 weeks	Fluoxetine	Placebo	+ BDI + HRSD	= Glycemic control
	Lustman et al., (1998)	51	10 weeks 6-month follow-up	CBT	Diabetes Education Program	+ BDI	= Glycemic control + at follow-up
	Lustman et al., (1997)	68	8 weeks	Nortriptyline	Placebo	+ BDI	= Glycemic control
HIV	Elliot et al., (1998)	75	12 weeks	Paroxetine or Imipramine	Placebo	+ HRSD	= CD4 cell count
	Rabkin et al., (1999)	120	8 weeks	Fluoxetine	Placebo	+ HRSD count	= CD4 cell
	Rabkin et al., (1994)	97	6 weeks	Imipramine	Placebo	+ HRSD	= CD4 cell count

^a“+” = Depression treatment improved outcome; “=” = no difference; “−“ = Depression treatment worsened outcome

HRSD = Hamilton Rating Scale for Depression; CBT = Cognitive Behavioral Therapy; BDI = Beck Depression Inventory; ICD-10 = International Statistical Classification of Diseases and Related Health Problems, Depressive Disorder; SCL-90 = Hopkins Symptoms Checklist-90 depression score; MI = Myocardial Infarction